Optimality, Future and Terminal Costs: Comment on “Adjuvant Trastuzumab Therapy for Early HER2-Positive Breast Cancer in Iran”

Noga Gershon; Yakir Berchenko

doi:10.1007/s40273-018-0621-x

Optimality, Future and Terminal Costs: Comment on “Adjuvant Trastuzumab Therapy for Early HER2-Positive Breast Cancer in Iran”

Noga Gershon, Yakir Berchenko

Department of Industrial Engineering and Management

Ben-Gurion University of the Negev

Research output: Contribution to journal › Letter › peer-review

Original language	American English
Pages (from-to)	383-384
Number of pages	2
Journal	PharmacoEconomics
Volume	36
Issue number	3
DOIs	https://doi.org/10.1007/s40273-018-0621-x
State	Published - 1 Mar 2018

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

All Science Journal Classification (ASJC) codes

Pharmacology
Health Policy
Public Health, Environmental and Occupational Health

Access to Document

10.1007/s40273-018-0621-x

Cite this

@article{0d7b611c19b64745b749c0bcc78ef972,

title = "Optimality, Future and Terminal Costs: Comment on “Adjuvant Trastuzumab Therapy for Early HER2-Positive Breast Cancer in Iran”",

author = "Noga Gershon and Yakir Berchenko",

year = "2018",

month = mar,

day = "1",

doi = "10.1007/s40273-018-0621-x",

language = "American English",

volume = "36",

pages = "383--384",

journal = "PharmacoEconomics",

issn = "1170-7690",

publisher = "Adis International Ltd",

number = "3",

}

TY - JOUR

T1 - Optimality, Future and Terminal Costs

T2 - Comment on “Adjuvant Trastuzumab Therapy for Early HER2-Positive Breast Cancer in Iran”

AU - Gershon, Noga

AU - Berchenko, Yakir

PY - 2018/3/1

Y1 - 2018/3/1

UR - http://www.scopus.com/inward/record.url?scp=85041924087&partnerID=8YFLogxK

U2 - 10.1007/s40273-018-0621-x

DO - 10.1007/s40273-018-0621-x

M3 - Letter

SN - 1170-7690

VL - 36

SP - 383

EP - 384

JO - PharmacoEconomics

JF - PharmacoEconomics

IS - 3

ER -

Optimality, Future and Terminal Costs: Comment on “Adjuvant Trastuzumab Therapy for Early HER2-Positive Breast Cancer in Iran”

UN SDGs

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Cite this